JP2015180657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015180657A5 JP2015180657A5 JP2015098029A JP2015098029A JP2015180657A5 JP 2015180657 A5 JP2015180657 A5 JP 2015180657A5 JP 2015098029 A JP2015098029 A JP 2015098029A JP 2015098029 A JP2015098029 A JP 2015098029A JP 2015180657 A5 JP2015180657 A5 JP 2015180657A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical composition
- optionally
- aging
- cell death
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000032677 cell aging Effects 0.000 claims 8
- 230000030833 cell death Effects 0.000 claims 8
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims 6
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 235000020956 nicotinamide riboside Nutrition 0.000 claims 3
- 239000011618 nicotinamide riboside Substances 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 229920001817 Agar Polymers 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 206010073306 Exposure to radiation Diseases 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 235000019483 Peanut oil Nutrition 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000019485 Safflower oil Nutrition 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 229920001615 Tragacanth Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940110456 cocoa butter Drugs 0.000 claims 1
- 235000019868 cocoa butter Nutrition 0.000 claims 1
- 235000005687 corn oil Nutrition 0.000 claims 1
- 239000002285 corn oil Substances 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 235000012343 cottonseed oil Nutrition 0.000 claims 1
- 239000002385 cottonseed oil Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008393 encapsulating agent Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims 1
- 229940093471 ethyl oleate Drugs 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 1
- 239000000347 magnesium hydroxide Substances 0.000 claims 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 239000000312 peanut oil Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229920001592 potato starch Polymers 0.000 claims 1
- 230000001698 pyrogenic effect Effects 0.000 claims 1
- 235000005713 safflower oil Nutrition 0.000 claims 1
- 239000003813 safflower oil Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000008159 sesame oil Substances 0.000 claims 1
- 235000011803 sesame oil Nutrition 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000000196 tragacanth Substances 0.000 claims 1
- 235000010487 tragacanth Nutrition 0.000 claims 1
- 229940116362 tragacanth Drugs 0.000 claims 1
- 125000005039 triarylmethyl group Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/053,185 | 2005-02-08 | ||
| US11/053,185 US7977049B2 (en) | 2002-08-09 | 2005-02-08 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012104652A Division JP2012176962A (ja) | 2005-02-08 | 2012-05-01 | 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015180657A JP2015180657A (ja) | 2015-10-15 |
| JP2015180657A5 true JP2015180657A5 (enExample) | 2016-05-19 |
Family
ID=36591266
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554337A Pending JP2008529502A (ja) | 2005-02-08 | 2006-02-08 | 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 |
| JP2012104652A Pending JP2012176962A (ja) | 2005-02-08 | 2012-05-01 | 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 |
| JP2015098029A Pending JP2015180657A (ja) | 2005-02-08 | 2015-05-13 | 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554337A Pending JP2008529502A (ja) | 2005-02-08 | 2006-02-08 | 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 |
| JP2012104652A Pending JP2012176962A (ja) | 2005-02-08 | 2012-05-01 | 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7977049B2 (enExample) |
| EP (1) | EP1851240B1 (enExample) |
| JP (3) | JP2008529502A (enExample) |
| AU (1) | AU2006212770B2 (enExample) |
| CA (1) | CA2595495C (enExample) |
| ES (1) | ES2401342T3 (enExample) |
| WO (1) | WO2006086454A2 (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2421269A1 (en) * | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| CA2529510A1 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
| US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| JP2007527418A (ja) | 2003-12-29 | 2007-09-27 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 肥満及びインシュリン耐性障害を治療又は防止するための組成物 |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US20090117543A1 (en) * | 2004-05-04 | 2009-05-07 | President And Fellows Of Harvard College | Methods and compositions for inducing sirtuins |
| ES2557810T3 (es) * | 2004-06-04 | 2016-01-28 | Washington University | Métodos y composiciones para tratar neuropatías |
| EP1794306B1 (en) * | 2004-09-24 | 2009-12-16 | Bayer BioScience N.V. | Stress resistant plants |
| AU2006204699B2 (en) * | 2005-01-13 | 2012-04-26 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| US20060229265A1 (en) * | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| US20090137681A1 (en) * | 2005-04-08 | 2009-05-28 | David A Sinclair | Sirtuin Inhibiting Compounds |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| EP1757284A1 (en) * | 2005-08-25 | 2007-02-28 | Santhera Pharmaceuticals (Schweiz) AG | Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy |
| ES2670927T3 (es) | 2005-11-18 | 2018-06-04 | Cornell Research Foundation, Inc. | Composiciones de nicotinoil ribósido y métodos de uso |
| WO2007101122A2 (en) * | 2006-02-24 | 2007-09-07 | University Of Chicago | Methods and compositions involving slc17a1 |
| US8158856B2 (en) * | 2006-03-21 | 2012-04-17 | Bayer Cropscience Nv | Stress resistant plants |
| WO2007136744A1 (en) * | 2006-05-19 | 2007-11-29 | The Johns Hopkins University | Crystal structure of a substrate complex of nampt/pbef/visfatin |
| US20090197824A1 (en) * | 2008-01-31 | 2009-08-06 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| US20090088404A1 (en) * | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| AU2008210327B2 (en) * | 2007-01-31 | 2011-06-16 | Methylation Sciences International Srl | Extended release pharmaceutical formulations of S-adenosylmethionine |
| US8180580B2 (en) * | 2007-02-01 | 2012-05-15 | The Wistar Institute | Method for identifying a compound that modulates SIR2 protein activity |
| EP2214698A2 (en) * | 2007-10-23 | 2010-08-11 | President and Fellows of Harvard College | Use of compounds activating sirt-3 for mimicking exercise |
| BRPI0819649A2 (pt) * | 2007-11-30 | 2017-01-10 | Daniel V Santi | método, organismo geneticamente modificado, e, célula de levedura recinbinante |
| JP5570731B2 (ja) * | 2008-02-28 | 2014-08-13 | 旭化成ファーマ株式会社 | ピロリン酸の測定方法 |
| WO2010065567A2 (en) * | 2008-12-01 | 2010-06-10 | Lifespan Extension Llc | Methods and compositions for altering health, wellbeing, and lifespan |
| CN107595841A (zh) | 2009-01-09 | 2018-01-19 | 得克萨斯州大学系统董事会 | 前神经原性化合物 |
| US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
| US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| WO2011011627A1 (en) | 2009-07-22 | 2011-01-27 | The Regents Of The University Of California | Cell-based systems for production of methyl formate |
| US8329208B2 (en) | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
| US20110027342A1 (en) * | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
| GB201007197D0 (en) * | 2010-04-30 | 2010-06-16 | Ge Healthcare Uk Ltd | Methods and kits for determining the toxicity of an agent |
| DK2590647T3 (en) | 2010-07-07 | 2018-02-12 | Univ Texas | Pro-neurogenic compounds |
| WO2012068463A2 (en) * | 2010-11-18 | 2012-05-24 | Beth Israel Deaconess Medicall Center, Inc. | Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt) |
| CA2840516A1 (en) * | 2011-06-29 | 2013-01-03 | President And Fellows Of Harvard College | Small molecule cd38 inhibitors and methods of using same |
| US9877981B2 (en) | 2012-10-09 | 2018-01-30 | President And Fellows Of Harvard College | NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
| US20150265642A1 (en) * | 2012-10-09 | 2015-09-24 | President And Fellows Of Harvard College | Nad biosynthesis and precursors in the prevention and treatment of inflammation |
| JP5877935B2 (ja) | 2012-10-17 | 2016-03-08 | メチレーション・サイエンシーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティＭｅｔｈｙｌａｔｉｏｎ Ｓｃｉｅｎｃｅｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓｒｌ | Ｓ−アデノシルメチオニンおよび没食子酸エステルを含む組成物 |
| CN105873937A (zh) | 2013-10-30 | 2016-08-17 | 可劳迈戴斯有限公司 | 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物 |
| EP3068388A4 (en) | 2013-11-11 | 2017-04-12 | Board of Regents of the University of Texas System | Neuroprotective compounds and use thereof |
| WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
| DK3129493T3 (da) * | 2014-04-09 | 2021-09-27 | Scripps Research Inst | Import af unaturlige eller modificerede nukleosidtriphosphater ind i celler via nukleinsyre-triphosphat-transportører |
| WO2015186068A1 (en) | 2014-06-02 | 2015-12-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Preparation and use of crystalline beta-d-nicotinamide riboside |
| CA2956163C (en) | 2014-07-24 | 2023-01-10 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| US9995758B1 (en) | 2014-10-31 | 2018-06-12 | Western Autotroph Company LLC | Methods and systems for controlling oxidative stress in humans and animals |
| CA2978069C (en) | 2015-03-09 | 2021-10-12 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| EP3288637B1 (en) | 2015-04-28 | 2022-09-14 | NewSouth Innovations Pty Limited | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity |
| JP2018515486A (ja) | 2015-05-01 | 2018-06-14 | ザ プロクター アンド ギャンブル カンパニー | ニコチンアミドリボシドを用いた皮膚外観の改善方法及びそのための組成物 |
| WO2016178949A1 (en) * | 2015-05-01 | 2016-11-10 | The Procter & Gamble Company | Method of improving skin health and compositions therefor |
| WO2017004101A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Skin care compositions comprising particles with nicotinamide riboside and methods of using the same |
| WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
| WO2017004100A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Encapsulated particles comprising nicotinamide riboside |
| BR112018002168B1 (pt) | 2015-08-05 | 2023-10-10 | Metro International Biotech, Llc | Composto, ou um estereoisômero ou sal do mesmo, uso do composto e composição que compreende um composto ou um sal farmaceuticamente aceitável do mesmo |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| JP6554540B2 (ja) | 2016-01-11 | 2019-07-31 | ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ | 皮膚状態を処置するための組成物 |
| AU2017239666B2 (en) * | 2016-03-31 | 2021-07-29 | Berkeley Lights, Inc. | Nucleic acid stabilization reagent, kits, and methods of use thereof |
| US10183036B2 (en) * | 2016-04-20 | 2019-01-22 | ChromaDex Inc. | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors |
| EP3538099A4 (en) | 2016-11-11 | 2020-06-17 | The Queen's University of Belfast | EFFICIENT AND SCALABLE SYNTHESIS OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS OF THEM, ADENYLYDINUCLEOTIDE CONJUGATES THEREOF AND NEW-WAY CRYSTALS |
| CN110234238B (zh) | 2016-11-29 | 2023-03-28 | 爱荷华大学研究基金会 | Nad前体用于改善母体健康和/或后代健康的用途 |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| WO2018129039A1 (en) | 2017-01-04 | 2018-07-12 | President And Fellows Of Harvard College | Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same |
| US10660838B2 (en) | 2017-06-23 | 2020-05-26 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
| AU2018300069C1 (en) | 2017-07-11 | 2025-11-20 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
| MA49770A (fr) | 2017-08-03 | 2021-05-26 | Synthorx Inc | Conjugués de cytokine destinés au traitement de maladies prolifératives et infectieuses |
| WO2019126482A1 (en) | 2017-12-22 | 2019-06-27 | Elysium Health, Inc. | Crystalline forms of nicotinamide riboside chloride |
| AU2019214858B2 (en) | 2018-01-30 | 2023-02-02 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| KR20210011964A (ko) | 2018-07-03 | 2021-02-02 | 더 프록터 앤드 갬블 캄파니 | 피부 병태를 치료하는 방법 |
| TW202535474A (zh) | 2019-02-06 | 2025-09-16 | 美商欣爍克斯公司 | Ｉｌ—２結合物及其使用方法 |
| WO2020174492A1 (en) | 2019-02-25 | 2020-09-03 | Celagenex Research (India) Pvt. Ltd. | Synergistic bioactive compositions for enhancing cellular energy |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| JP7702934B2 (ja) * | 2019-08-14 | 2025-07-04 | メトロ インターナショナル バイオテック，エルエルシー | ニコチンアミドアデニンジヌクレオチドの差次的モジュレーションのための化合物及び組成物 |
| CN110973260A (zh) * | 2019-12-11 | 2020-04-10 | 杨力 | 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用 |
| CN111394268B (zh) * | 2019-12-20 | 2021-06-18 | 合肥康诺生物制药有限公司 | 基因工程菌及其构建方法、应用，生产nad+的方法 |
| JP7590462B2 (ja) | 2020-06-01 | 2024-11-26 | ザ プロクター アンド ギャンブル カンパニー | ビタミンｂ３化合物の皮膚への浸透を改善する方法 |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| JP2023537073A (ja) * | 2020-08-07 | 2023-08-30 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | 一塩基多型及び炎症状態の治療 |
| CN117545488A (zh) | 2021-05-27 | 2024-02-09 | 麦德龙国际生物科技有限责任公司 | 烟酸单核苷酸及其酯的结晶固体以及其制作和使用方法 |
| WO2023086770A1 (en) * | 2021-11-10 | 2023-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Neuroprotection gene therapy |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
| AU2024274445A1 (en) | 2023-05-15 | 2025-11-27 | Bonafide Health, Llc | Sleep-improving compositions and methods of use |
Family Cites Families (168)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179937A (en) | 1978-06-02 | 1979-12-25 | Ocean Ecology Ltd. | Sound measuring device |
| FR2543550B1 (fr) * | 1983-04-01 | 1985-08-09 | Cortial | Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JPS63152309A (ja) * | 1986-08-11 | 1988-06-24 | Lion Corp | 皮膚外用剤 |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| DE3733017A1 (de) | 1987-09-30 | 1989-04-13 | Bayer Ag | Stilbensynthase-gen |
| US5689046A (en) | 1987-09-30 | 1997-11-18 | Bayer Aktiengesellschaft | Stilbene synthase gene |
| US4970200A (en) * | 1988-03-01 | 1990-11-13 | Schering Aktiengesellschaft | Agent for treatment of Parkinson's disease |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE4107396A1 (de) * | 1990-06-29 | 1992-01-02 | Bayer Ag | Stilbensynthase-gene aus weinrebe |
| US5063507A (en) | 1990-09-14 | 1991-11-05 | Plains Cotton Cooperative Association | Goods database employing electronic title or documentary-type title |
| JP3214049B2 (ja) | 1992-03-09 | 2001-10-02 | 史衛 佐藤 | シス−オレフィンの製造法 |
| DE4232899C2 (de) * | 1992-09-30 | 1995-02-23 | Birkmayer Joerg Univ Prof Dr | Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer |
| IL107642A0 (en) * | 1992-11-20 | 1994-02-27 | Amgen Inc | Progenitor b cell stimulating factor |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| ATE399873T1 (de) | 1993-07-13 | 2008-07-15 | Centelion | Defekte adenovirus-vektoren und deren verwendung in der gentherapie |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| US6048903A (en) * | 1994-05-03 | 2000-04-11 | Robert Toppo | Treatment for blood cholesterol with trans-resveratrol |
| CA2192442C (en) | 1994-06-10 | 2007-09-25 | Imre Kovesdi | Complementary adenoviral vector systems and cell lines |
| DE69534166T2 (de) | 1994-10-28 | 2006-03-09 | Trustees Of The University Of Pennsylvania | Rekombinanter adenovirus und methoden zu dessen verwendung |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
| DE4440200A1 (de) * | 1994-11-10 | 1996-05-15 | Bayer Ag | DNA-Sequenzen und ihre Verwendung |
| AU709498B2 (en) | 1994-12-12 | 1999-09-02 | Genetic Therapy, Inc. | Improved adenoviral vectors and producer cells |
| DE4444238A1 (de) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden |
| US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| CA2213439A1 (en) | 1995-02-24 | 1996-08-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for administering gene therapy vectors |
| US5688676A (en) | 1995-06-07 | 1997-11-18 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| WO1997008298A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| IT1276225B1 (it) * | 1995-10-17 | 1997-10-27 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per |
| FR2741238B1 (fr) * | 1995-11-17 | 2001-11-30 | Goemar Lab Sa | Utilisation du chlorure d'aluminium comme agent eliciteur de la synthese du resveratrol |
| US6124125A (en) * | 1996-01-08 | 2000-09-26 | Trustees Of Dartmouth College | AMP activated protein kinase |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| US6184248B1 (en) * | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| US5827898A (en) * | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
| IT1291113B1 (it) * | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
| FR2766176B1 (fr) * | 1997-07-15 | 1999-10-29 | Caudalie | Compositions a base de derives de resveratrol |
| US6270780B1 (en) * | 1997-07-25 | 2001-08-07 | Chesebrough-Pond's Usa Co., Division Of Conopco | Cosmetic compositions containing resveratrol |
| BR9803596A (pt) * | 1997-09-23 | 2000-04-25 | Pfizer Prod Inc | Derivados do resorcinol. |
| WO1999021565A1 (en) * | 1997-10-24 | 1999-05-06 | Cornell Research Foundation, Inc. | Nutritional supplement for cerebral metabolic insufficiencies |
| US6008260A (en) | 1998-01-09 | 1999-12-28 | Pharmascience | Cancer chemopreventative composition and method |
| US6414037B1 (en) | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
| AT407821B (de) * | 1998-03-24 | 2001-06-25 | Franz Dr Stueckler | Mittel auf der basis von naturstoffen |
| US6245814B1 (en) * | 1998-05-08 | 2001-06-12 | Calyx Therapeutics, Inc. | Diphenylethylene compounds |
| US6331633B1 (en) | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
| US6624197B1 (en) * | 1998-05-08 | 2003-09-23 | Calyx Therapeutics, Inc. | Diphenylethylene compounds |
| US6448450B1 (en) * | 1998-05-08 | 2002-09-10 | Calyx Therapeutics, Inc. | 1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene for diabetes treatment |
| US6022901A (en) * | 1998-05-13 | 2000-02-08 | Pharmascience Inc. | Administration of resveratrol to prevent or treat restenosis following coronary intervention |
| GB9816781D0 (en) | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| US20030086986A1 (en) * | 1998-08-06 | 2003-05-08 | Bruijn Chris De | Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives |
| US6197834B1 (en) * | 1998-09-01 | 2001-03-06 | Northeastern Ohio Universities College Of Medicine | Method of inhibiting formation of infectious herpes virus particles |
| ES2258337T3 (es) | 1998-09-08 | 2006-08-16 | Cornell Research Foundation, Inc. | Uso de inhibidores de la ciclooxigenasa-2 para el tratamiento de enfermedades inflamatorias de cabeza y cuello. |
| US6656925B2 (en) * | 1998-09-09 | 2003-12-02 | Advanced Medical Instruments | Composition and method of treating arthritis |
| IT1302365B1 (it) * | 1998-10-09 | 2000-09-05 | Sigma Tau Healthscience Spa | Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali |
| US20030078212A1 (en) | 1998-10-30 | 2003-04-24 | Jia-He Li | Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| US6361815B1 (en) * | 1998-12-21 | 2002-03-26 | Pure World Botanicals, Inc. | Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use |
| US6190716B1 (en) * | 1999-02-17 | 2001-02-20 | Scott O. Galbreath, Jr. | Method for preparing a grape derived product |
| FR2790645B1 (fr) | 1999-03-12 | 2001-06-08 | Arkopharma Laboratoires | Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols |
| US6878381B2 (en) | 1999-03-22 | 2005-04-12 | Pfizer, Inc | Resorcinol composition |
| AU773675B2 (en) * | 1999-04-12 | 2004-06-03 | Dainippon Sumitomo Pharma Co., Ltd. | Method for analyzing the amount of intraabdominal adipose tissue |
| FR2795643B1 (fr) * | 1999-07-02 | 2004-06-11 | Oreal | Composition cosmetique raffermissante comprenant au moins un hydroxystilbene en association avec de l'acide ascorbique |
| AU765724B2 (en) | 1999-08-13 | 2003-09-25 | University Of Maryland Biotechnology Institute | Compositions for treating viral infections, and methods therefor |
| AU770563B2 (en) * | 1999-09-03 | 2004-02-26 | Alfasigma S.p.A | Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| AU7596100A (en) * | 1999-09-21 | 2001-04-24 | Rutgers, The State University | Resveratrol analogs for prevention of disease |
| US6264995B1 (en) * | 1999-10-19 | 2001-07-24 | Thomas Newmark | Herbal composition for reducing inflammation and methods of using same |
| US6358517B1 (en) * | 1999-10-22 | 2002-03-19 | Unilever Home & Personal Care Usa, Division Of Conopco | Cosmetic compositions containing resveratrol and retinoids |
| US20020002200A1 (en) * | 2000-02-04 | 2002-01-03 | Bishwagit Nag | Novel diphenylethylene compounds |
| US7452664B2 (en) | 1999-12-15 | 2008-11-18 | Massachusetts Institute Of Technology | Methods for identifying agents which alter histone protein acetylation |
| US6416806B1 (en) * | 2000-03-20 | 2002-07-09 | James H. Zhou | Herbal caffeine replacement composition and food products incorporating same |
| AU2001245977A1 (en) | 2000-03-23 | 2001-10-03 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of menopause |
| IT1318425B1 (it) | 2000-03-24 | 2003-08-25 | D B P Dev Biotechnological Pro | Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi. |
| IT1317034B1 (it) | 2000-05-30 | 2003-05-26 | Istituto Di Medicina Speriment | Metodo di estrazione di prodotti ad attivita' farmaceutica da piantespermatofite, prodotti cosi' ottenuti e loro impiego in medicina, in |
| US6475530B1 (en) | 2000-05-31 | 2002-11-05 | Eric H. Kuhrts | Methods and compositions for producing weight loss |
| ITNA20000037A1 (it) | 2000-06-02 | 2001-12-02 | Dev Biotechnological Proces Se | Filtro solare multifunzione innovativo. |
| ITNA20000036A1 (it) | 2000-06-02 | 2001-12-02 | Dev Biotechnological Proces Se | Nuovi approcci terapeutici per il trattamento della forfora. |
| IT1318565B1 (it) | 2000-06-09 | 2003-08-27 | World Pharma Tech Ltd | Integratore alimentare proenergetico a base di nadh octocosanolo evitamina e. |
| US6795856B1 (en) | 2000-06-28 | 2004-09-21 | Accountability International, Inc. | System and method for monitoring the internet access of a computer |
| US6319523B1 (en) | 2000-06-29 | 2001-11-20 | James H. Zhou | Composition and method for inhibiting oral bacteria |
| US20020120008A1 (en) * | 2000-06-29 | 2002-08-29 | Seymour Benzer | Life extension of drosophila by a drug treatment |
| WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
| DE10034320A1 (de) * | 2000-07-14 | 2002-02-07 | Inst Pflanzenbiochemie Ipb | Verfahren zur Beeinflussung des Sinapingehalts in transgenen Pflanzenzellen und Pflanzen |
| FR2812195B1 (fr) * | 2000-07-28 | 2003-07-11 | Oreal | Compositions a application topique comprenant des hydroxystilbenes glucosyles et utilations |
| US20020110604A1 (en) * | 2000-08-11 | 2002-08-15 | Ashni Naturaceuticals, Inc. | Composition exhibiting synergistic antioxidant activity |
| US6410596B1 (en) * | 2000-08-16 | 2002-06-25 | Insmed Incorporated | Compositions containing hypoglycemically active stillbenoids |
| US6541522B2 (en) * | 2000-08-16 | 2003-04-01 | Insmed Incorporated | Methods of using compositions containing hypotriglyceridemically active stilbenoids |
| US6552085B2 (en) * | 2000-08-16 | 2003-04-22 | Insmed Incorporated | Compositions containing hypoglycemically active stilbenoids |
| AU2002236438A1 (en) | 2000-11-08 | 2002-05-21 | Massachusetts Institute Of Technology | Compositions and methods for treatment of mild cognitive impairment |
| WO2002039956A2 (en) * | 2000-11-15 | 2002-05-23 | Rutgers, The State University Of New Jersey | Black tea extract for prevention of disease |
| US20030165854A1 (en) * | 2000-12-05 | 2003-09-04 | Cunningham Mary Jane | Marker genes responding to treatment with toxins |
| US20030082647A1 (en) * | 2000-12-12 | 2003-05-01 | Reenan Robert A. | Transporter protein |
| US20040005574A1 (en) * | 2002-07-08 | 2004-01-08 | Leonard Guarente | SIR2 activity |
| AU2002226650A1 (en) | 2001-01-18 | 2002-07-30 | Arnold Hoffman | Redox therapy for tumors |
| US20030191064A1 (en) | 2001-01-23 | 2003-10-09 | Kopke Richard D. | Methods for preventing and treating loss of balance function due to oxidative stress |
| US20020192310A1 (en) | 2001-02-02 | 2002-12-19 | Bland Jeffrey S. | Medical composition for managing hormone balance |
| FR2820320B1 (fr) * | 2001-02-02 | 2003-04-04 | Oreal | Suspension de nanospheres de principe actif lipophile stabilisee par des polymeres hydrodispersibles |
| US20030190381A1 (en) | 2001-02-02 | 2003-10-09 | Bland Jeffrey S. | Medical composition for balancing bodily processes |
| CA2439109A1 (en) * | 2001-02-20 | 2002-10-17 | Uab Research Foundation | Polyphenolics for enhancing endothelial cell-mediated fibrinolysis |
| US6300377B1 (en) * | 2001-02-22 | 2001-10-09 | Raj K. Chopra | Coenzyme Q products exhibiting high dissolution qualities |
| ITPI20010014A1 (it) * | 2001-03-05 | 2002-09-05 | Ivo Pera | Composto per filtri per sigarette,o altri articoli da fumo,a base di sostanze antiossidanti ed il filtro cosi'ottenuto |
| US20020177614A1 (en) * | 2001-03-23 | 2002-11-28 | Merril Carl R. | Methods for treating nuerodegenerative diseases including alzheimer's |
| US20030044946A1 (en) * | 2001-04-03 | 2003-03-06 | Longo Valter D. | Genes, mutations, and drugs that increase cellular resistance to damage and extend longevity in organisms from yeast to humans |
| US6387416B1 (en) * | 2001-04-05 | 2002-05-14 | Thomas Newmark | Anti-Inflammatory herbal composition and method of use |
| US20030180719A1 (en) * | 2001-04-13 | 2003-09-25 | Thomas Herget | Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections |
| US20030004142A1 (en) * | 2001-04-18 | 2003-01-02 | Prior Christopher P. | Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway |
| WO2002085327A2 (en) * | 2001-04-18 | 2002-10-31 | Oraltech Pharmaceuticals, Inc. | Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract |
| US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| US6426061B1 (en) * | 2001-04-20 | 2002-07-30 | Weiwei Li | Method and composition for preventing sweat-related odor |
| US7183316B2 (en) | 2001-05-03 | 2007-02-27 | Cornell Research Foundation, Inc. | Treatment of HPV caused diseases |
| US6368617B1 (en) * | 2001-05-15 | 2002-04-09 | Reliv' International, Inc. | Dietary supplement |
| EP1532244A4 (en) * | 2001-06-14 | 2005-12-14 | Bristol Myers Squibb Co | NEW HISTONIC HUMAN DEACETYLASES |
| US7241743B2 (en) * | 2001-06-15 | 2007-07-10 | The Trustees Of Columbia University In The City Of New York | Sir2α-based therapeutic and prophylactic methods |
| US7384920B2 (en) | 2001-07-26 | 2008-06-10 | Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla | Use of stilbene compounds in the manufacture of medicament for the prevention and treatment of diabetes or retrovirus-associated diseases |
| US20030044474A1 (en) * | 2001-08-03 | 2003-03-06 | Shaklee Corporation | High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability |
| US7396546B2 (en) | 2001-08-06 | 2008-07-08 | The Quigley Corporation | Anti-microbial compositions and methods of using same |
| JP2005524382A (ja) * | 2001-08-15 | 2005-08-18 | エリクサー ファーマスーティカルズ インコーポレイテッド | 年齢関連マーカー |
| US6841578B2 (en) * | 2001-08-16 | 2005-01-11 | Stephen T. Sonis | Treatment and prevention of mucositis in cancer patients |
| US6680342B2 (en) * | 2001-09-20 | 2004-01-20 | Mayo Foundation For Medical Education And Research | Methods and compositions for inhibiting the proliferation of prostate cancer cells |
| US20030055114A1 (en) * | 2001-09-20 | 2003-03-20 | Charles Young | Methods and compositions for inhibiting the proliferation of prostate cancer cells |
| US20030054053A1 (en) * | 2001-09-20 | 2003-03-20 | Charles Young | Methods and compositions for inhibiting the proliferation of prostate cancer cells |
| US6656969B2 (en) * | 2001-09-20 | 2003-12-02 | Mayo Foundation For Medical Education And Research | Methods and compositions for inhibiting the proliferation of prostate cancer cells |
| US7326685B2 (en) * | 2001-09-21 | 2008-02-05 | The Administrators Of The Tulane Educational Fund | Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| US20030082116A1 (en) * | 2001-09-28 | 2003-05-01 | Closure Medical Corporation | Adhesive compositions containing dual function stabilizers and active agents |
| US7119110B2 (en) * | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| EP1304161B1 (en) * | 2001-10-19 | 2007-02-28 | Pacific Corporation | Thermotropic liquid crystal polymer microcapsules, a method for preparing the same, and cosmetic compositions containing the same |
| DE60105820D1 (de) * | 2001-10-22 | 2004-10-28 | Pera Ivo E | Zusammensetzung zur Reduzierung oder Entwöhnung von Nikotinabhängigkeit |
| US6767563B2 (en) * | 2001-10-30 | 2004-07-27 | Michael D. Farley | Immune functions |
| US20030118536A1 (en) * | 2001-11-06 | 2003-06-26 | Rosenbloom Richard A. | Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| AU2002356992A1 (en) * | 2001-11-21 | 2003-06-10 | Albert Einstein College Of Medicine Of Yeshiva University | Sir2 products and activities |
| US6544564B1 (en) * | 2001-11-27 | 2003-04-08 | Michael Donald Farley | Cytotoxic pharmaceutical composition |
| FR2832630B1 (fr) * | 2001-11-28 | 2005-01-14 | Oreal | Composition cosmetique et/ou dermatologique contenant au moins un actif hydrophile sensible a l'oxydation stabilise par au moins un copolymere de n-vinylimidazole |
| US20030118617A1 (en) * | 2001-12-21 | 2003-06-26 | Avon Products, Inc. | Resveratrol analogues |
| NZ516366A (en) * | 2001-12-24 | 2004-07-30 | Enzo Nutraceuticals Ltd | Increased lifespan formulation using pine bark flavonoid extract |
| US7406384B2 (en) * | 2001-12-26 | 2008-07-29 | The Regents Of The University Of California | System and method for identifying networks or ternary relationships in complex data systems |
| US6824790B2 (en) * | 2002-01-09 | 2004-11-30 | Enzrel Inc. | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
| JP4860906B2 (ja) | 2002-03-08 | 2012-01-25 | プロテミックス コーポレイション リミティド | 心疾患および／または関連心不全の予防および／または治療 |
| WO2003077860A2 (en) | 2002-03-13 | 2003-09-25 | Biophysica, Inc. | BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES |
| EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| DE60202603T2 (de) | 2002-03-28 | 2005-12-29 | Council Of Scientific And Industrial Research | 8-(c-beta-d-glucopyranosyl)-7,3',4'-trihydroxyflavone, verfahren zur isolation aus pterocarpus marsupium und pharmazeutische zusammensetzung zur behandlung von diabetes |
| US20030224077A1 (en) | 2002-04-08 | 2003-12-04 | Societe L'oreal S.A. | Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase |
| JP2005529123A (ja) * | 2002-04-24 | 2005-09-29 | リサーチ ディベロップメント ファンデーション | 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果 |
| WO2003094833A2 (en) * | 2002-05-10 | 2003-11-20 | Orchid Chemicals & Pharmaceuticals Limited | A new stereoselective route to produce tris-o-substituted-(e)-( 3,5-dihydroxyphenyl)-2-(4- hydroxyphenyl)ethene |
| US7531337B2 (en) | 2002-06-07 | 2009-05-12 | Wisconsin Alumni Research Foundation | Method of controlling acetylation of metabolic enzymes |
| CA2488609A1 (en) | 2002-06-10 | 2003-12-18 | Oklahoma Medical Research Foundation | A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| DE10230961A1 (de) | 2002-07-10 | 2004-02-12 | Lorenz, Peter, Dr. | Verwendung von Oxyresveratrol als Neuroprotektivum |
| AU2003242965B2 (en) * | 2002-07-11 | 2009-02-05 | Dermipsor Ltd. | Composition and methods for the treatment of skin disorders |
| WO2004009539A2 (en) | 2002-07-19 | 2004-01-29 | Orchid Chemicals And Pharmaceuticals Limited | Method for the conversion of a z-isomer into e-isomer |
| CA2421269A1 (en) | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| DE10244282A1 (de) | 2002-09-23 | 2004-04-01 | Merck Patent Gmbh | Zubereitung mit antioxidanten Eigenschaften |
| EP1418164A1 (en) | 2002-11-07 | 2004-05-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists |
| US20040224039A1 (en) * | 2003-02-12 | 2004-11-11 | Donald Brucker | Compositions and methods for the treatment of diseases and disorder associated with oxidative damage |
| CN1794925A (zh) | 2003-05-27 | 2006-06-28 | 帝斯曼知识产权资产管理有限公司 | 新颖的营养药物性组合物及其用途 |
| CA2529510A1 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
| US20050136429A1 (en) * | 2003-07-03 | 2005-06-23 | Massachusetts Institute Of Technology | SIRT1 modulation of adipogenesis and adipose function |
| US20050004052A1 (en) * | 2003-07-03 | 2005-01-06 | Technion Research & Development Foundation Ltd. | Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes |
| US20050038125A1 (en) * | 2003-08-15 | 2005-02-17 | Smit Hobbe Friso | Method for the treatment of arthritis and pain |
| US20050049208A1 (en) * | 2003-09-03 | 2005-03-03 | Kaufmann Doug A. | Method of treating and method of preventing diabetes |
| CA2538759C (en) | 2003-09-12 | 2015-11-03 | Elixir Pharmaceuticals, Inc. | Substituted heterocyclic compounds as sirtuin inhitibitors |
| WO2005053609A2 (en) | 2003-11-26 | 2005-06-16 | Guilford Pharmaceuticals Inc. | Methods of nad+-dependent deacetylase inhibitors |
| JP2007527418A (ja) | 2003-12-29 | 2007-09-27 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 肥満及びインシュリン耐性障害を治療又は防止するための組成物 |
| DE502004006574D1 (de) * | 2004-06-03 | 2008-04-30 | Balcke Duerr Gmbh | Hydraulisches Aufweitverfahren und Vorrichtung dafür |
| ES2557810T3 (es) * | 2004-06-04 | 2016-01-28 | Washington University | Métodos y composiciones para tratar neuropatías |
| EP1794306B1 (en) | 2004-09-24 | 2009-12-16 | Bayer BioScience N.V. | Stress resistant plants |
| US20060229265A1 (en) | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US8158856B2 (en) | 2006-03-21 | 2012-04-17 | Bayer Cropscience Nv | Stress resistant plants |
-
2005
- 2005-02-08 US US11/053,185 patent/US7977049B2/en not_active Expired - Lifetime
-
2006
- 2006-02-08 AU AU2006212770A patent/AU2006212770B2/en active Active
- 2006-02-08 WO PCT/US2006/004397 patent/WO2006086454A2/en not_active Ceased
- 2006-02-08 EP EP06734562A patent/EP1851240B1/en active Active
- 2006-02-08 ES ES06734562T patent/ES2401342T3/es active Active
- 2006-02-08 CA CA2595495A patent/CA2595495C/en active Active
- 2006-02-08 JP JP2007554337A patent/JP2008529502A/ja active Pending
-
2011
- 2011-04-19 US US13/089,969 patent/US20120022013A1/en not_active Abandoned
-
2012
- 2012-05-01 JP JP2012104652A patent/JP2012176962A/ja active Pending
-
2015
- 2015-05-13 JP JP2015098029A patent/JP2015180657A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015180657A5 (enExample) | ||
| EP3134411B1 (en) | Purine derivatives as cd73 inhibitors for the treatment of cancer | |
| JP2019514884A5 (enExample) | ||
| JP2020531418A5 (enExample) | ||
| JP2011517683A5 (enExample) | ||
| JP2013541503A5 (enExample) | ||
| JP2018076328A5 (enExample) | ||
| JP2017522277A5 (enExample) | ||
| CA2998189A1 (en) | Methods for treating arenaviridae and coronaviridae virus infections | |
| JP2013518107A5 (enExample) | ||
| JP2017512186A5 (enExample) | ||
| CN101142198A (zh) | 用于治疗疾病的异唑坎布雷它斯丁衍生物 | |
| JP2019516739A5 (enExample) | ||
| JP2019507111A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2016536360A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2017510610A5 (enExample) | ||
| JP2015512946A5 (enExample) | ||
| JP2016511753A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2015535831A5 (enExample) | ||
| JP2016501838A5 (enExample) | ||
| JP2015051983A5 (enExample) | ||
| JP2016516773A5 (enExample) |